Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of EYP001a in Healthy Male Subjects
NCT03110276Phase 1Completed
- Sponsor
- ENYO Pharma
- Start
- Aug 2016
- Primary completion
- Mar 2017
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in hepatitis B (HBV) comparing EYP001a with Placebo (2 arms). Primary endpoint: Number of subjects reported with adverse events, serious adverse events at 21 days. Started Aug 2016; status: completed.
02
Drugs
vonafexor
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT03110276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03110276.